Medtech M&A 'rebounded' in 2025 as softer valuations drove deal competition: report
Medtech M&A 'rebounded' in 2025 as softer valuations drove deal competition: report
Medtech M&A 'rebounded' in 2025 as softer valuations drove deal competition: report
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.